th lymphovascular invasion or with multicenter/ multifocal disease.Breast cancer represents one of the three most common gynecological cancers, with each subtype having distinct risk profile and treatment strategies. Optimal therapy for each case depends not only on tumor subtype and cancer stage, but also on patient preferences. https://www.selleckchem.com/products/rmc-6236.html Thus, the final therapeutic choice seems complicated to be reached. In addition, frequent relapses and the aesthetic effects have led to the search for more effective and less invasive methods. Surgical interventions have become less complex and new hormonal and chemotherapeutic drugs are established, that promise great results, either combined to surgical treatment or used exclusively. Luteolin is a representative of natural flavonoid that has proven to modulate various signaling pathways involved in cancer development. Recent data demonstrate that luteolin induces apoptotic cell death via antioxidant activity, acting as an anticancer agent against various types of human malignancies including breast cancer. The aim of this review is to summarize latest data considering the therapeutic role of luteolin in breast cancer.Axillary lymph node dissection (ALND) was and still is an important part of breast cancer treatment despite the fact the sentinel lymph node biopsy (SLNB) has revolutionized breast cancer surgery. SLNB provides the same prognostic information as ALND but with significantly less morbidity. The results of numerous trials conducted over the past 20 years have crowned SLNB as the gold standard for early breast cancer treatment. ALND represents a very standardized intervention with precise landmarks and boundaries. An accurate technique and a good knowledge of axillaÃÂ¢ÃÂÃÂ anatomy are mandatory for a correct and complete ALND. But even with a meticulous and careful technique of dissection, a comprehensive ALND may be associated with important morbidity. Nowadays ALND indications are continuously evolving, but the procedure has still an indisputable place in breast cancer treatment.Breast cancer is one of the most severe health issues globally, but the therapy advancements and the constant adaptation of treatment protocols radically changed its prognoses. This article review of the literature from a surgical perspective, thus allowing for the optimum detection and placement of its role and benefits in the surgical and oncology therapeutics. The role of surgery becomes controversial, with sometimes "pretentious" techniques, hard to quantify benefits and challenges that require a thorough assessment prior to opting for surgery. Another interesting aspect is the relative lack of guidelines for such cases with an extreme lesion plurimorphism. This is the very reason for the term "advanced breast cancer" NOT covering all possible situations, leaving room for niches difficult to frame within a therapy plan.The indications for the use of neoadjuvant chemotherapy (NAC) for the management of breast cancer have broadened immensely in recent years. Initially intended mostly for inoperable breast cancers, this modality has then became the standard of care for locally advanced cancers. This treatment allowed safe surgical margin resection and in many patients with large tumors it allowed breast conserving surgery, avoiding the need for mastectomy. As clinical experience with NAC has increased along with the introduction of novel medications and better understanding of tumor biology, the indications for its use have become even more common for the treatment of some subtypes of early breast cancer. Furthermore, the use of NAC was found to have an impact on decreasing the need for axillary lymph node dissection in selected patients presenting initially with positive lymph nodes. This article will review the current practice and indications of NAC in breast cancer as well as some controversial issues regarding the surgical management of the breast and the axilla following neoadjuvant treatment.Bachground Robotic breast surgery is an emergent procedure with encouraging preliminary results. The aim of this study is to assess the feasibility and the safety of robotic nipple sparing mastectomy (RNSM) with immediate prosthetic breast reconstruction (IPBR). Methods This is a prospective study including from December 2015 to January 2020 all RNSM surgeries with IPBR, in patients with moderate ptosis and A B or C cup. The primary endpoint was the rate of major necrosis. Secondary endpoints were conversion rate, postoperative complications (infections, hematoma, implant exposure), aesthetic results and quality of life. Results 79 patients underwent 138 RNSM with IPBR. The average follow-up was 28 months. 2 procedures required conversion. Two cases of major necrosis occurred (1.4%). 9 surgical site infections were observed (6.5%), 4 infections could be treated with implant replacement. Unfortunately, 5 others resulted in implant loss. 4 other implant losses occurred 2 due to major necrosis, and 2 due to periprosthetic capsula. In total, 9 implants were lost (6.5%). Esthetical results were mostly very satisfying and quality of life was not affected by the mastectomy. Conclusions RSNM with IPBR was associated with low rates of major necrosis. It is a safe and reproducible procedure that allows breast reconstruction without visible scar.When at the end of last year Professor Traian Patrascu asked me to coordinate an issue of the journal "Chirurgia" dedicated to breast cancer, I was both surprised and intrigued. For two reasons firstly it seemed to me so little time had passed since the previous issue about this disease and perhaps there weren't many new things to say and secondly I believed that the only topic worth discussing nowadays was the disease that overshadowed anything else COVID-19. Nevertheless I realized that he was right. More than 3 years had passed since the previous issue and there were many updates related to this subject and COVID-19 or not, the treatment of breast cancer must continue. I am grateful to those who answered to my invitation to write an article. I was amazed by the huge number and the quality of the papers received. They were so numerous that we decided to have a supplement of the journal dedicated to breast cancer edited with the contribution of the Romanian Society of Breast Surgery and Oncology. The COVID-19 pandemic has affected the entire planet in almost every aspect of life, including the medical system.